Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma
Citations Over TimeTop 1% of 2018 papers
Abstract
Anaplastic thyroid cancer (ATC) is a devastating disease with a dismal prognosis. Patients who have disease confined to the thyroid and who are able to undergo complete surgery and chemoradiation stand the best chance for survival. Unfortunately, nearly 50% of patients have distant metastases at diagnosis, and most present with locally advanced, unresectable tumors. Nevertheless, BRAF-mutated ATC patients represent a subset of cases who can benefit from a combination therapy with BRAF and MEK inhibitors. Here, a patient is presented with end-stage, locally advanced, unresectable ATC who was treated with this combination. Immunotherapy with pembrolizumab was added at the first sign of progression after which he achieved a partial response to therapy, enabling a complete surgical resection followed by postoperative chemoradiation to be undertaken. This novel neoadjuvant approach to BRAF-mutated ATC should be studied in further in clinical trials.
Related Papers
- → Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro(2017)35 cited
- → Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer(2017)20 cited
- → Risk of cumulative toxicity after complete melanoma response with pembrolizumab(2017)8 cited
- [Personal experience with simultaneous transplantation of pancreas segment and kidney].(1995)
- The role of Nuclear Medicine in the management of patients with anaplastic and poorly differentiated Thyroid Cancer.(2021)